-

09:33:47 AM

SWTX Stock News

SWTX - SpringWorks Therapeutics Inc

06/07/23 7:00 AM

Nasdaq : SWTX

conferences

SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a

RHEA-AI

neutral

06/05/23 6:30 AM

Nasdaq : SWTX

SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing

RHEA-AI

positive

05/30/23 6:30 AM

Nasdaq : SWTX

clinical trial

SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it has achieved full enrollment in its

RHEA-AI

neutral

05/25/23 5:05 PM

Nasdaq : SWTX

clinical trial

SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting

- Nirogacestat Treatment Demonstrated Rapid, Sustained and Consistent Reductions in Pain Compared to Placebo Using Multiple Assessment Tools - - Substantial Reductions in MRI-Assessed Tumor Volume and T2 Hyperintensity Observed with Nirogacestat Compared to Placebo - STAMFORD, Conn., May 25, 2023

RHEA-AI

neutral

05/24/23 7:00 AM

Nasdaq : SWTX

conferences

SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a

RHEA-AI

neutral

05/11/23 12:14 PM

Nasdaq : SWTX

clinical trial

SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that data from two collaborator-sponsored

RHEA-AI

positive

05/03/23 6:30 AM

Nasdaq : SWTX

SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

– NDA for Nirogacestat in Adults with Desmoid Tumors Accepted by the FDA and Granted Priority Review; PDUFA Action Date Set for August 27, 2023 – – Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors Published in the New England Journal of Medicine – – Encouraging Clinical Data

RHEA-AI

neutral

05/02/23 7:00 AM

Nasdaq : SWTX

conferences

SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a

RHEA-AI

neutral

04/17/23 2:32 PM

Nasdaq : SWTX

clinical trial

SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced that they will present updated clinical data from the Phase 1b

RHEA-AI

neutral

04/17/23 2:30 PM

Nasdaq : SWTX

clinical trial

MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

MapKure, LLC, SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced that they will present updated

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

SWTX Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitespringworkstx.com
Security nameSpringWorks Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees227
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing

About SpringWorks Therapeutics Inc

springworks therapeutics is a mission-driven medicines company dedicated to developing innovative potential new treatments for unserved and underserved patient communities. originally conceived by pfizer, springworks presents a groundbreaking new model for collaboration rooted in connecting scientists, biopharmaceutical partners, patient groups, funders and philanthropists to advance and deliver transformative science to patients. through our partnerships, we remain focused on providing innovative treatments an additional avenue for development, with our launch pipeline focused on advancing potential programs for four diseases, all of which currently have no cure, including desmoid tumor, neurofibromatosis, hereditary xerocytosis and post-traumatic stress disorder. our name is a reflection of our approach to drug development: we’re springing into action to deliver treatments to people who are in great need and without alternatives.